Qsymia® (phentermine/topiramate extended-release) – Expanded indication
June 24, 2022 - The FDA approved Vivus’ Qsymia (phentermine/topiramate extended-release), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex.
Top